13-Dihydrocarminomycin
13-Dihydrocarminomycin (compound D788-12) is the major metabolite of the antitumor antibiotic Carminomycin (HY-B2171). 13-Dihydrocarminomycin has weak antitumor activity.
For research use only. We do not sell to patients.
- CAS No.: 62182-86-9
- Formula: C26H29NO10
- Molecular Weight:515.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
In Vitro
13-Dihydrocarminomycin (compound D788-12; 0-1 mM; 48 h) inhibits the growth of L1210 cells, with an IC50 value of 0.06 µg/mL (120 µM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:L1210 cells
-
Concentration:0-1 mM
-
Incubation Time:48 h
-
Result:Suppressed cell growth (IC50 = 0.06 µg/mL or 120 µM).
Chemical Information
-
CAS No. 62182-86-9
-
Molecular Weight 515.51
-
Formula C26H29NO10
-
SMILES
OC1=C(C2=C(C3=C1C[C@](O)(C[C@@H]3O[C@H]4C[C@@H]([C@@H]([C@@H](O4)C)O)N)C(C)O)O)C(C5=C(C2=O)C(O)=CC=C5)=O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
[1]. Yoshimoto A, et al. Anthracycline metabolites from baumycin-producing Streptomyces sp. D788. II. New anthracycline metabolites produced by a blocked mutant strain RPM-5. J Antibiot (Tokyo). 1993 Jan;46(1):56-64. [Content Brief]
[2]. Poteshnykh AV, et al. Determination of carminomycin and its basic metabolite 13-dihydrocarminomycin by a highly efficient liquid chromatographic method with a fluorescent detector. Antibiotiki. 1982 Nov;27(11):820-3. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
13-Dihydrocarminomycin Related Classifications
HY-135176 Related Classifications
Powered by Bioz